Colorcon shows new 'work anywhere' tablet coating at CPHI
Opadry QX is a new tablet film coating, designed to meet the manufacturing flexibility, batch consistency and efficiencies.
Responding to increased demand worldwide, leading film coatings systems supplier Colorcon will focus on key innovative products designed to optimize process time.
Opadry QX, a new tablet film coating, is designed to meet the manufacturing flexibility, batch consistency and efficiencies companies manufacturing across different sites and geographies are increasingly striving for.
"This revolutionary advance greatly reduces production and preparation times, ensuring coating process efficiency and cost savings in all types of equipment, from traditional pans to continuous coating equipment,” says Deborah Taylor, Global Market Communications Manager. “The current market focus is on continuous manufacturing and developments associated with batch consistency and manufacturing process improvements. Colorcon’s goal was to develop an innovative fully formulated system, suitable for fast application and scalable across a range of coating equipment, while still delivering colour uniformity and a high-quality finish."
The system can be applied over a broad range of process conditions and always results in a premium quality finish for tablets, even those containing temperature-sensitive active ingredients. This means that multinational pharmaceutical companies can easily transition the manufacture of drug products across continents, overcoming challenges often met with equipment differences.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.